Date: 12th September, 2026
Regulatory Compliance Update
- Dishman Carbogen Amcis Limited's wholly owned subsidiary, Carbogen Amcis AG, successfully completed its first U.S. Food and Drug Administration (FDA) inspection
- The inspection was conducted at the manufacturing site located in Vionnaz, Switzerland
- The inspection was completed without any Form 483 observations
- The inspection was completed on September 11, 2026 (referenced as "yesterday" relative to the announcement date of September 12, 2026)
- This successful inspection reflects the company's strong focus on quality parameters across the company and its subsidiaries
- The company's sites worldwide remain approved by major regulatory agencies
No material disclosures under the following sections:
KMP / Board / Auditor Changes, Dividend Declaration or Non-Declaration, Board Meeting Outcomes, Financial Results, Auditor's Report, Disinvestment / Strategic Actions, Media Release / Investor Communication, Other Operational / Legal / Strategic Disclosures